HYQVIA is a subcutaneous immunoglobulin (Ig) replacement therapy designed for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders that affect the body's immune system. This medication is a combination of human normal immunoglobulin and recombinant human hyaluronidase, the latter of which increases the absorption and distribution of the immunoglobulin. Administered under the skin, HYQVIA helps to boost the immune system by providing the necessary antibodies that the patient's body is unable to produce sufficiently. This treatment is typically recommended for adults and is designed to be administered once every 3 to 4 weeks, offering a convenient option for those requiring regular immunoglobulin therapy. By helping to maintain adequate antibody levels, HYQVIA plays a crucial role in protecting individuals with PI against infections.